Xbrane Biopharma Q1 2024: Softer than anticipated - Redeye

Redeye leaves its initial comments on Xbrane's Q1 report, which came in softer than we had pencilled on both revenues and EBIT. However, sales to end customer grew 30% q/q which is on track with expectations.

Länk till analysen i sin helhet: https://www.redeye.se/research/1008144/xbrane-biopharma-q1-2024-softer-than-anticipated?utm_source=finwire&utm_medium=RSS